Oncology Medical News about breakthrough pain; cancer; intranasal fentanyl spray

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: A phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period
Clinical Therapeutics, 08/26/09

Kress HG et al. – Intranasal fentanyl spray (INFS), at 50, 100, and 200 micrograms, was associated with an onset of activity at 10 min and effective tx of breakthrough pain compared with placebo.

Methods

Phase III, double-bline, randomized, placebo-controlled, crossover trial
120 adults with cancer receiving a stable dose of long-term opioid tx for the control of background pain
Patients were treated at home with 50, 100, or 200 micrograms of INFS or placebo for 3 weeks, followed by a 10-month, phase when they received their effective dose of INFS

Results

The pain intensity difference at 10 minutes (PID10) with INFS was 2-fold that with placebo
The mean response rate with all 3 doses of INFS was 51.1% vs. 20.9% with placebo
The prevalence of AEs was 19.8% (nausea [4.5%] and vertigo [1.8%])

<< Previous
Nuclear expression of Snail1 in borderline and malignant...

Next >>
Rituximab in combination with high-dose methylprednisolone for...